Prophylaxis of venous thromboembolism
=====================================

Patients undergoing elective arthroplasty (hip or knee) or other major orthopedic surgery are at high risk of developing venous thromboembolism (VTE), which represents a dangerous event in terms of mortality and morbidity with high social impact and costs.

Randomized clinical trials (RCT) estimate that, in absence of a thromboprophylaxis, the incidence of venographically proven VTE ranges from 45% to 57% after total hip replacement (THR) surgery, 36% to 60% after hip fracture surgery (HFS), and 40% to 84% after total knee replacement (TKR) surgery ([@b22-vhrm-4-0983]; [@b23-vhrm-4-0983]).

Although low-dose unfractionated heparin (UFH) ([@b7-vhrm-4-0983]) and aspirin ([@b1-vhrm-4-0983]) have been reported more effective than no prophylaxis in patients undergoing THR, these agents have been abandoned today in favor of low-molecular-weight heparins (LMWHs), vitamin K antagonists, and synthetic derivatives of factor Xa inhibitor, such as fondaparinux.

In fact, several studies ([@b6-vhrm-4-0983]; [@b39-vhrm-4-0983]; [@b54-vhrm-4-0983]; [@b53-vhrm-4-0983]; German Hip Arthroplasty Trial Group 1992; [@b8-vhrm-4-0983]; [@b26-vhrm-4-0983]) and meta-analyses ([@b49-vhrm-4-0983]; [@b21-vhrm-4-0983]; [@b32-vhrm-4-0983]) have confirmed that LMWHs are more effective than low-dose or adjusted-dose UFH with a relative risk reduction of 25%--50%. Moreover, LMWH are as effective as vitamin K antagonists in the TVE prevention, but they have a lower hemorrhagic risk ([@b30-vhrm-4-0983]; [@b52-vhrm-4-0983]; [@b18-vhrm-4-0983]; [@b59-vhrm-4-0983]; [@b3-vhrm-4-0983]; [@b26-vhrm-4-0983]; [@b57-vhrm-4-0983]).

While the phophylactic efficacy of LMWH is today unquestioned, the treatment schedule (when to begin, how many times a day, and for how long) is a still debated point.

The standard protocols in North America recommend the administration of a first LMWH dose between 12 and 24 hours after surgery, whereas in Europe the prophylaxis is often begun pre-operatively (10--12 hours before surgery) ([@b62-vhrm-4-0983]). Several authors have compared different prophylactic regimens in order to ascertain whether the first dose is more effective if given pre- or post-operatively. It has been shown that starting the prophylaxis near the time of the operation is the most critical point, whether or not the first dose is administered pre- or post-operatively ([@b33-vhrm-4-0983]; [@b62-vhrm-4-0983]; [@b3-vhrm-4-0983]; [@b58-vhrm-4-0983]). A review of RCTs has shown a reduction of 40%--50% in the DVT rate in THR patients when the prophylaxis was begun between 2 hours before and 8 hours after surgery, although the pre-operative administration of heparin seemed to involve a higher hemorrhagic risk ([@b29-vhrm-4-0983]). The risk can be reduced, however, by giving an early post-operative (6--8 hours) low dose of heparin, and by increasing the doses of heparin in the following 24 hours or later, according to the course of post-operative bleeding ([@b28-vhrm-4-0983]; [@b23-vhrm-4-0983]).

On the other hand, the risk for TVE is not confined to the immediate post-operative period. According to literature, most of symptomatic TVE complications (12%--35%) occur after discharge; thus, several authors suggest that the prophylactic treatment should be continued for longer times (6--8 weeks) whenever risk factors are present, and be stopped only when full weight on the treated limb is resumed. It has been reported that continuation of prophylaxis for at least 2 weeks may further reduce the TVE risk by an additional 50% ([@b69-vhrm-4-0983]; [@b59-vhrm-4-0983]; [@b23-vhrm-4-0983]; [@b25-vhrm-4-0983]; [@b67-vhrm-4-0983]; [@b2-vhrm-4-0983]; [@b57-vhrm-4-0983]).

Finally, the risk for TVE in minor orthopedic surgery should not be underestimated even if an antithromboembolic prophylaxis is rarely used in these patients. The presence of concomitant risk factors for thromboembolism, as well as the frequent use of a tourniquet with subsequent revascularization in performing these operations, may explain the high rate of TVE complications in this "minor" surgery. Thus, appropriately long prophylaxis with LMWH is also indicated in these patients ([@b50-vhrm-4-0983]; [@b44-vhrm-4-0983]; [@b47-vhrm-4-0983]).

Low-molecular-weight heparins
=============================

LMWHs are extracted from UFH of animal origin with a molecular weight (MW) ranging between 4,000 and 30,000 Da. The activity of LMWHs is mediated by their binding to antithrombin III (AT III); however, because of fragmentation, the coagulation factors IIa and Xa are affected differently by AT III and, therefore, the antithrombotic activity is separated by the anticoagulant effect because of a larger anti-Xa activity compared with anti-IIa activity.

The structural changes in LMWHs modify the pharmacokinetics compared with UFH: the absorption after subcutaneous (sc) administration is almost complete, predictable, and reliable. The smaller molecules have a lower binding to plasma and tissue proteins and, consequently, a higher antithrombotic activity is available in the plasma; moreover, LMWHs undergo reduced liver metabolism and have an increased renal elimination. The plasma half-life of LMWHs is therefore longer than that of UFH, although to varying degrees among different molecules, thus allowing for a single daily administration.

The anti-Xa/anti-IIa activity rate expresses the relationship between the doses producing the desired antithrombotic activity, and those producing the undesired anticoagulant effects. This way of expressing the activity of the LMWH has a clinical meaning during DVT prophylaxis, the main objective of prophylaxis being to inhibit the formation and growth of fibrin thrombus at the site of DVT without affecting the systemic coagulation. It is generally recognized that the greater is the fractioning of the AT III-binding chain, the shorter and more homogeneous the synthetic molecule, and the more selective the inhibitory activity on factor Xa compared with factor IIa.

Parnaparin
==========

Our aim was to review the available clinical data on parnaparin, a LMWH that is effective and generally well tolerated in the prevention of VTE, as well as in the treatment of arterial and venous diseases ([@b42-vhrm-4-0983]). The data source was PubMed, which was searched for "parnaparin" or "Fluxum", returning 4 reviews and 25 experimental works; no restriction on language and time was applied. Moreover, published reports not listed in PubMed were provided by Alfa Wassermann S.p.A. (Bologna, Italy). Dosages of parnaparin reported in this review (3,200, 6,400 and 12,800 IUaXa) were calculated using the chromogenic method from the European Pharmacopoea Standard of LMWH. These units are equivalent to those mentioned in clinical papers from the 1980s through to the mid 1990s (7,500, 15,000, and 30,000 aXaU), which were calculated using the chromogenic method from the 4th International Standard of Unfractionated Heparin.

Pharmacology and pharmacokinetics
---------------------------------

Parnaparin is a LMWH obtained with an original and patented procedure of fragmentation, which guarantees the homogeneity of fragments in terms of molecular weifht; thus, all the fragments have the right length to optimize the dissociation between the antithrombotic and anticoagulant activities (anti-Xa/anti-IIa ratio \>4).

The most interesting characteristics of parnaparin are its speed of action after sc administration (T~max~ ≈3 hours) and its plasma half-life (about 6 hours), which are ideal for a single daily administration (Summary of Product Characteristics approved by Regulatory Authorities); therefore, parnaparin provides a rapid antithrombotic protection in urgent situations, and it has a minimal risk for drug accumulation and consequent hemorrhagic risk ([Table 1](#t1-vhrm-4-0983){ref-type="table"}).

In principle, the predictable and constant pharmacokinetics of parnaparin makes its use much easier and simpler in day-by-day clinical practice; moreover, like other LMWHs, the low influence of parnaparin on coagulation means that repeated lab tests are not needed monitor coagulation times. The consequent practical advantage is a simpler management of post-operative DVT prophylaxis at home.

Experimental observations show the ability of parnaparin to prevent in vitro the activation of platelets and leukocytes, and to inhibit the formation of leukocyte-platelet aggregates ([@b40-vhrm-4-0983]; [@b35-vhrm-4-0983]; [@b41-vhrm-4-0983]).

The neutralization of parnaparin by protamine chloride has been studied in vitro on coagulation tests (APTT, anti-Xa activity). The activity of parnaparin on APTT has been completely neutralized by protamine with a parnaparin/protamine ratio of IUaXa/20 μg, whereas anti-Xa activity has been partially but substantially neutralized by protamine ([@b45-vhrm-4-0983]).

Parnaparin in major orthopedic surgery
--------------------------------------

Clinical evidence for the effectiveness of LMWH and, especially, of parnaparin, in the prevention of DVT in patients undergoing major orthopedic surgery for arthroplasty and trauma has been published over several years. Prophylaxis with parnaparin has been reported to be more effective than placebo ([@b64-vhrm-4-0983]) and more advantageous than UFH. In a series of 140 patients, DVT was detected in legs either by Doppler sonography or ^125^I-fibrinogen uptake test in 7.1% and 10% of patients treated, respectively, with parnaparin 3,200 IUaXa sc (= 7,500 aXaU) twice daily or calcium UFH 5,000 IU sc 3 times daily, given for 7 days ([@b6-vhrm-4-0983]). In another trial aimed at preventing post-operative VTE after hip fracture, 49 patients were randomly treated either with parnaparin 3,200 IUaXa twice daily or with UFH 5,000 IU tid. Screening for thrombosis was performed with ^125^I-fibrinogen leg scanning and strain-gauge plethysmography, and positive results were confirmed by venography. In this study, the rate of venographically proven DVT was 20% in the parnaparin group and 29% in the UFH group. The difference was not statistically significant since the number of randomized patients was rather small, but there was an interesting trend in favor of parnaparin, as 1 pulmonary embolism and 2 deaths occurred in the UFH group, and none in the parnaparin group ([@b53-vhrm-4-0983]).

[@b3-vhrm-4-0983] performed a multicenter study on 381 patients at high risk of DVT undergoing major orthopedic surgery; they were treated with UFH, parnaparin or other LMWHs, given around the time of surgery and continued at home for 10--90 days according to the type of operation or risk factors. Parnaparin was administed once daily at doses ranging between 3,200 and 4,250 IUaXa/day. DVT was diagnosed clinically and instrumentally (Echo Color Doppler). The authors concluded that LMWHs were significantly more effective than UFH (DVT rate 10.3% vs 16.6%), and that parnaparin was even slightly more effective (DVT 8.4%) than other LMWHs, although a significant difference was not achieved ([Table 2](#t2-vhrm-4-0983){ref-type="table"}).

Moreover, while one case of major bleeding was observed for each treatment groups (ie, UFH, parnaparin and other LMWH), episodes of minor bleeding (such as a local hematoma at the site of injection or surgical wound or a need for a surgical drainage) were observed in 17.85%, 6.06%, and 11.76%, respectively, of UFH, parnaparin, and other LMWH-treated patients. Other adverse drug reactions (ADRs) (such as pain or irritation at the injection site), were observed in 25.0%, 7.4%, and 32.4% of patients treated, respectively, with UFH, parnaparin, and other LMWHs ([Table 3](#t3-vhrm-4-0983){ref-type="table"}).

The slightly higher antithrombotic activity achieved with parnaparin and other LMWHs compared with UFH demonstrates that a higher level of inhibition of Xa is associated with administration of a LMWH with no increase hemorrhagic risk. Thus, the use of parnaparin appears to be safer in orthopedic prophylaxis, as suggested by [@b39-vhrm-4-0983], who reported a statistically significant lower incidence of side effects (ie, local hematomas) in parnaparin- than in UFH-treated patients (25.0% vs 64.7%).

The more appropriate time for starting prophylaxis with parnaparin was investigated by [@b33-vhrm-4-0983]. Forty patients undergoing THR were randomly treated with parnaparin 6,400 IUaXa in once-daily administration starting either 2 hours before or 2 hours after the surgical operation. The treatment lasted 7 days. The results showed that the incidence of DVT was very similar and extremely low in the two groups, only 1 patient in each group having a positive diagnosis on phlebography. Although the sample size was relatively small, the authors concluded that prophylaxis was effective in both groups with a DVT rate approaching 5%, and without any significant difference between groups in the amount of perioperative bleeding.

Parnaparin in minor orthopedic surgery
--------------------------------------

Over the past 20 years, arthroscopy has become an important tool in orthopedics for virtually every joint. Complication rates for arthroscopy are low but not absent (\<8.2%), including DVT and PE, whose incidence may be increased either by specific risk factors of patients (such as old age, obesity, and concomitant venous diseases) or by the local ischemia secondary to the use of a tourniquet ([Table 4](#t4-vhrm-4-0983){ref-type="table"}). Thus, the need for prophylaxis in minor orthopedic surgery should not be undervalued ([@b55-vhrm-4-0983]; [@b17-vhrm-4-0983]; [@b48-vhrm-4-0983]).

Clinical studies show that adequate prophylaxis can be achieved with LMWHs ([Table 5](#t5-vhrm-4-0983){ref-type="table"}).

In order to obtain information about the efficacy and safety of parnaparin in minor orthopedic surgery under tourniquet ischemia, we have identified prospectively 509 patients in our center. Knee arthroscopy represented the most frequent surgery (68% of the survey), followed by removal of a fixation device or other foreign material (14%), foot surgery (8.1%), arthroscopy of the ankle and shoulder (1.6%), biopsy (5.1%), and other surgery (3.3%).

The antithromboembolic prophylaxis with once-daily parnaparin (3,200--4,250 IUaXa) was initiated within 6 hours after the end of surgery and extended until full weight bearing and walking was resumed (10.5 ± 9.1 days). All the patients underwent compression ultrasound on days 8 to 10 or with the onset of clinical signs suggesting DVT. Instrumental tests never revealed proximal DVT, while minor bleeding (hematoma in surgical site with hemoglobin decrease \<2 g/dL) was found in 7 cases (1.4%) ([@b47-vhrm-4-0983]).

Other uses of parnaparin
------------------------

Parnaparin has been also employed for TVE prophylaxis in non-orthopedic surgery. A multicenter study performed by [@b65-vhrm-4-0983] on 610 patients undergoing general (mainly abdominal) surgery, a statistically significant difference was observed between parnaparin 3,200--6,400 IUaXa once daily and UFH in the rate of post-operative DVT (3.2% vs 6.3%; p \< 0.01), although the difference in the incidence of PE between treatment groups did not reach significance (0.3 vs 1.0%).

Parnaparin has been used for VTE prophylaxis in bariatric surgery. Ten severely obese patients (body mass index \>50 kg/m^2^) have been treated with increasing single daily doses of parnaparin (3,200, 4,250, and 6,400 IUaXa) on the three consecutive days leading up to biliointestinal bypass surgery. The highest dose was continued from the day of surgery until day 30 (recovery period). During the pre-operative dosing phase, parnaparin dose-dependently prolonged APTT, with the 6,400 IUaXa dose significantly prolonging aPTT vs the lower doses. Meanwhile, the 4,250 and 6,400 IUaXa once-daily doses increased anti-factor Xa and anti-factor IIa activity. After surgery, 1 patient with heparin resistance experienced pulmonary embolization. No bleeding complications were observed. The dose-response data reported in this preliminary study suggest that parnaparin doses of 4,250 and 6,400 IUaXa may provide effective prophylaxis for VTE in patients undergoing bariatric surgery. However, given the small number of patients, larger, well-controlled trials are required to confirm these findings ([@b20-vhrm-4-0983]).

[@b4-vhrm-4-0983] have compared the effectiveness of nadroparin and parnaparin in the non-prophylactic treatment of DVT in terms of the evolution of thrombosis, in a randomized prospective study in 91 patients. Overall, there were 3 cases (3.3%) of progression of thrombosis despite therapy with LMWH, 2 cases (5%) in the nadroparin group, and 1 case (2%) in the parnaparin group (not significant). The Doppler ultrasound in the follow-up showed a complete resolution of 56% of DVT at an average of 6.1 ± 4.6 months. Valve competence recovered in 65.9% of cases with no significant difference between the two groups.

Parnaparin has been successfully used in the treatment of coronary artery diseases (CAD). Parnaparin 6,400 IUaXa once daily sc for 7 days was more effective than UFH given intravenously for 48 hours, then sc (UFH 5,000 IU every 6 hours) for 5 days in a randomized, multicenter study in patients (n = 897) with unstable angina. The incidence of the triple composite endpoint (death, acute myocardial infarction \[MI\] or the need for myocardial revascularizations in the 7 days after the start of treatment) was significantly lower in the parnaparin than in the UFH group (7% vs 11%; p = 0.034) ([@b56-vhrm-4-0983]).

Similarly, in patients with an acute STEMI, sc parnaparin 4,250 IUaXa every 12 hours for 7 days was associated with a lower incidence of a triple composite endpoint of death, acute MI, or the need for myocardial revascularization in the 45 days after the start of treatment than intravenous UFH administered for 3 days followed by subcutaneous UFH 7,500 IU every 12 hours for 4 days (27% vs 42%; p = 0.03) ([@b68-vhrm-4-0983]). Moreover, in patients with stable angina, parnaparin 6,400 IUaXa once daily, together with conventional therapy, significantly increased exercise time compared with placebo ([@b43-vhrm-4-0983]).

Finally, in patients with peripheral arterial obstructive disease a long-term treatment (6--8 months) with parnaparin 6,400 IUaXa once daily sc significantly improved the pain-free walking time/distance compared with baseline in several studies (Palmieri et al 1988; [@b37-vhrm-4-0983]; [@b5-vhrm-4-0983]; [@b61-vhrm-4-0983]). The extent of improvement with parnaparin was similar to that demonstrated with UFH in one study ([@b15-vhrm-4-0983]).

Tolerability of parnaparin
--------------------------

In humans, a higher rate of post-operative bleeding has been observed to related closely to the dose administered: at a prophylactic dose (3,200--6,400 IUaXa/day) the risk of bleeding is statistically not significant, and in any case lower than that observed with UFH ([@b38-vhrm-4-0983]; [@b3-vhrm-4-0983]). LMWHs do not cross the human placenta and are not detected in fetal blood during the first 6 months of pregnancy ([@b19-vhrm-4-0983]; [@b51-vhrm-4-0983]); therefore, they are also safe in pregnant women ([@b23-vhrm-4-0983]; [@b11-vhrm-4-0983]). Although rare episodes of immunomediated thrombocytopenia due to the use of other LMWHs have been reported ([@b34-vhrm-4-0983]; [@b46-vhrm-4-0983]), thrombocytopenia related to the use of parnaparin has not yet been observed.

At a local level, the tolerability of parnaparin seems better than that of UFH, with a lower rate of hematomas, pain, and burning in the injection site ([@b9-vhrm-4-0983]; [@b66-vhrm-4-0983]; [@b36-vhrm-4-0983]; [@b13-vhrm-4-0983]; [@b3-vhrm-4-0983]; [@b4-vhrm-4-0983]).

Conclusions
===========

A review of the literature shows that parnaparin, like other LMWHs, is effective and well tolerated when used for prophylaxis of post-operative VTE in orthopedic surgery. Its effectiveness seems to be far superior to that of UFH, and comparable with other LMWHs when initiated pre- or post-operatively near the time of surgery and continued at home for a period depending on the type of operation. Besides the clinical advantages, parnaparin and other LMWHs enable a simpler home management of the prophylaxis since they can be administered once a day and do not require continuous lab tests.
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###### 

Pharmacokinetic parameters of unfractionated heparins and low-molecular-weight heparins

               Absorption   Tmax         t½            Anti-Xa/Anti-IIa
  ------------ ------------ ------------ ------------- ------------------
  Sodium UFH   15%--30%     3 hours      1 hour        1
  Tinzaparin   90%          4--6 hours   1.5 hours     1.5
  Dalteparin   90%          3--4 hours   4 hours       2.6
  Reviparin    95%          3--4 hours   3 hours       3.5
  Enoxaparin   100%         3 hours      4.4 hours     4
  Nadroparin   98%          4--6 hours   8--10 hours   \>4
  Parnaparin   \>90%        3 hours      6 hours       \>4

###### 

Rate of deep vein thrombosis in patients who underwent surgery for total hip replacment

                                                         No. patients   No. DVT
  ------------------------------------------------------ -------------- ----------------------
  UFH                                                    12             2 (16.67%)
  Other LMWHs                                            29             3 (10.34%)
  RR[a](#tfn1-vhrm-4-0983){ref-type="table-fn"} vs UFH                  0.624 (0.098--1.148)
  Parnaparin                                             59             5 (8.47%)
  RR vs UFH                                                             0.463 (0.079--2.727)
  RR vs other LMWHs                                                     0.832 (0.224--1.756)

^a^Odds ratios (RR) were calculated with the 95% confidence limits with reference to UFH ([@b3-vhrm-4-0983]).

**Abbreviations:** DVT, deep vein thrombosis; LMWH, low-molecular-weight heparins; UFH, unfractionated heparins.

###### 

Rate of major and minor bleeding and other adverse drug reactions (ADR) observed with unfractionated heparins, parnaparin and other low-molecular-weight heparins ([@b3-vhrm-4-0983])

                No. patients   No. major bleedings   No. minor bleedings   No. other ADRS
  ------------- -------------- --------------------- --------------------- ----------------
  UFH           28             1 (3.57%)             5 (17.85%)            7 (25.00%)
  Parnaparin    231            1 (0.43%)             14 (6.06%)            17 (7.36%)
  Other LMWHs   102            1 (0.98%)             12 (11.76%)           33 (32.35%)

**Abbreviations:** ADRS, artificial disc replacement surgery; LMWH, low-molecular-weight heparins; UFH, unfractionated heparins.

###### 

Prospective uncontrolled trials, without heparin prophylaxis, in knee arthroscopy using objective methods for detecting deep vein thrombosis

  Study                No. patients   Diagnosis method              Rate of venous thrombosis (no./%)   
  -------------------- -------------- ----------------------------- ----------------------------------- -------
  [@b63-vhrm-4-0983]   48             Venography                    2                                   4.2%
  [@b70-vhrm-4-0983]   85             Compression ultrasonography   3                                   3.5%
  [@b10-vhrm-4-0983]   67             Compression ultrasonography   1                                   1.5%
  [@b16-vhrm-4-0983]   190            Venography                    6                                   3.2%
  [@b14-vhrm-4-0983]   184            Venography                    33                                  17.9%
  [@b31-vhrm-4-0983]   239            Venography                    7                                   2.9%
  [@b71-vhrm-4-0983]   117            Venography                    5                                   4.3%
  [@b12-vhrm-4-0983]   102            Color Duplex                  8                                   7.41%
  Total                1,032                                        65                                  6.29%

Adapted with permission from [@b71-vhrm-4-0983]. Prevention of venous thromboembolism after knee arthroscopy with low-molecular weight heparin (reviparin): results of a randomized, controlled trial. *Arthroscopy*, 17:393--9. Copyright © Elsevier Ltd, and reproduced with permission from [@b47-vhrm-4-0983]. Prophylaxis of venous thromboembolism in minor orthopedic surgery with parnaparin. *Clin Appl Thromb Hemost*, 13:249--58. Copyright © Sage publications.

###### 

Rate of deep vein thrombosis in patients undergoing knee arthroscopy and receiving different low-molecular-weight heparin prophylactic treatment (revision of the literature)

  LMWH          Dose (IU/die)   Study                No. patients   Diagnostic method        DVT rate (No./%)
  ------------- --------------- -------------------- -------------- ------------------------ ------------------
  Reviparin     1,750           [@b71-vhrm-4-0983]   116            Eco-color Doppler        1/0.86%
  Dalteparin    2,500--5,000    [@b44-vhrm-4-0983]   66             Compression ultrasound   1/1.52%
  Dalteparin    5,000           [@b60-vhrm-4-0983]   101            Duplex ultrasound        12/11.88%
  Nandroparin   3,075           [@b27-vhrm-4-0983]   101            Unknown                  5/4.95%
  Parnaparin    3,200--4,250    [@b47-vhrm-4-0983]   509            Compression ultrasound   0/0.00%

**Abbreviations:** DVT, deep vein thrombosis; LMWH, low-molecular-weight heparins; UFH, unfractionated heparins.
